Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov 15;132(22):e164747.
doi: 10.1172/JCI164747.

Does treating with anti-PD-1 to improve glomerular health come without a cost?

Kenar D Jhaveri  1 , Abhijat Kitchlu  2 , Ala Abudayyeh  3
Affiliations
Comment

Does treating with anti-PD-1 to improve glomerular health come without a cost?

Kenar D Jhaveri et al. J Clin Invest. .
No abstract available

Keywords: Cancer immunotherapy; Chronic kidney disease; Nephrology.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: KDJ serves as a consultant for PMV Pharmaceuticals, Secretome, George Clinicals, and Calliditas. KDJ is the current copresident of the American Society of Onconephrology (ASON) and is a paid contributor to UpToDate.com. AA is a founding member of the ASON. AK administers funds from Amgen Inc. and Jassen Inc. to support the University Health Network Onco-Nephrology Fellowship. AK is a founding member of the ASON.

Figures

Figure 1
Figure 1. Spectrum of kidney injury associated with ICIs with a focus on glomerular-associated diseases.
Anti-GBM, anti-glomerular basement membrane disease. Glomerular disease data are from Kitchlu et al. (3). Figure created using BioRender.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Pippin JW, et al. Upregulated PD-1 signaling antagonizes glomerular health in aged kidneys and disease. J Clin Invest. 2022;132(16):e156250. doi: 10.1172/JCI156250. - DOI - PMC - PubMed
    1. Gupta S, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9(10):e003467. doi: 10.1136/jitc-2021-003467. - DOI - PMC - PubMed
    1. Kitchlu A, et al. A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep. 2020;6(1):66–77. - PMC - PubMed
    1. Toda MG, et al. Minimal change disease associated with durvalumab. Kidney Int Rep. 2021;6(10):2733–2734. doi: 10.1016/j.ekir.2021.08.021. - DOI - PMC - PubMed
    1. Mamlouk O, et al. Checkpoint inhibitor-related renal vasculitis and use of rituximab. J Immunother Cancer. 2020;8(2):e000750. doi: 10.1136/jitc-2020-000750. - DOI - PMC - PubMed